Compare HUT & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUT | DVA |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 13.5B |
| IPO Year | 2023 | 2003 |
| Metric | HUT | DVA |
|---|---|---|
| Price | $120.67 | $214.33 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 4 |
| Target Price | $65.20 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 3.7M | 660.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.87 |
| Revenue | $235,118,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $161.69 | $3.85 |
| Revenue Next Year | N/A | $3.07 |
| P/E Ratio | ★ N/A | $74.31 |
| Revenue Growth | ★ 44.79 | 6.46 |
| 52 Week Low | $17.87 | $101.00 |
| 52 Week High | $140.80 | $215.33 |
| Indicator | HUT | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 72.97 |
| Support Level | $39.84 | $189.09 |
| Resistance Level | $140.80 | N/A |
| Average True Range (ATR) | 10.50 | 5.18 |
| MACD | -1.43 | 0.17 |
| Stochastic Oscillator | 65.55 | 98.21 |
Hut 8 Corp is an energy infrastructure platform that integrates power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.